Synthesis of (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside
- Autores: Khalikova M.J.1, Roziqov U.A.1, Skrylkova A.S.2, Egorov D.M.2, Safarov S.S.1
 - 
							Afiliações: 
							
- V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
 - St. Petersburg State Institute of Technology (Technical University)
 
 - Edição: Volume 60, Nº 4 (2024)
 - Páginas: 516-522
 - Seção: Articles
 - URL: https://vietnamjournal.ru/0514-7492/article/view/672180
 - DOI: https://doi.org/10.31857/S0514749224040137
 - EDN: https://elibrary.ru/RYNANK
 - ID: 672180
 
Citar
Texto integral
Resumo
The article presents a method for the preparation of (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside from (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-1,2-O-isopropylidene-α-L-talofuranoside by successive treatment of the latter with a 20% solution of hydrochloric acid in aqueous methanol, followed by treatment with benzoyl chloride in dry pyridine. A promising use of methyl (1S,2S,3R,4R,5S)-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside for the synthesis of new modified nucleosides after its acetylation has also been shown.
Texto integral
Sobre autores
M. Khalikova
V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
														Email: diavoly@mail.ru
				                					                																			                												                	Tajiquistão, 							ul. Ayni, 299/2, Dushanbe, 734063						
U. Roziqov
V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
														Email: diavoly@mail.ru
				                					                																			                												                	Tajiquistão, 							ul. Ayni, 299/2, Dushanbe, 734063						
A. Skrylkova
St. Petersburg State Institute of Technology (Technical University)
														Email: diavoly@mail.ru
				                					                																			                												                	Rússia, 							Moskovskii prosp., 26, St. Petersburg, 190013						
D. Egorov
St. Petersburg State Institute of Technology (Technical University)
							Autor responsável pela correspondência
							Email: diavoly@mail.ru
				                	ORCID ID: 0000-0003-3744-9306
				                																			                												                	Rússia, 							Moskovskii prosp., 26, St. Petersburg, 190013						
S. Safarov
V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
														Email: diavoly@mail.ru
				                	ORCID ID: 0000-0002-7193-6135
				                																			                												                	Tajiquistão, 							ul. Ayni, 299/2, Dushanbe, 734063						
Bibliografia
- Fischer E., Piloty O. Ber. Dtsch. Chem. Ges. 1891, 24, 4214–4225. doi: 10.1002/cber.189102402322
 - Eugenio F., Lourdes R. J. Biol. Chem. 2019, 294, 2249–2255. doi: 10.1074/jbc.CL119.007397.
 - Jeanloz R.W., Fletcher H. G. Adv. Carbohydr. Chem. 1951, 6, 135–174. doi: 10.1016/S0096–5332(08)60066–1.
 - Mao-Chin L., Mei-Zhen L., Diane E. M., Alan C. S. Nucleosid. Nucleotid. Nucleic. Acids. 2005, 24, 45–62. doi: 10.1081/NCN-46784.
 - Hassan A.E.A., Abou-Elkhair R.A.I., Parker W. B., Allan P. W., Secrist III J. A. Bioorg. Chem. 2016, 65, 9–16. doi: 10.1016/j.bioorg.2015.12.006.
 - Chhikara B.S., Parang K. Expert Opin. Drug Deliv. 2010, 7, 1399–1414. doi: 10.1517/17425247.2010.527330.
 - Li Y., Li P., Li Y., Zhang R., Yu P., Ma Z., Kainov D. E., de Man R. A., Peppelenbosch M. P., Pan Q. Antivir. Res. 2020, 184, 104967. doi: 10.1016/j.antiviral.2020.104967.
 - Cihák A. Oncology. 1974, 30, 405–422. doi 10.1159/ 000224981.
 - Liliemark J. Clin. Pharmacokinet. 1997, 32, 120–131. doi: 10.2165/00003088–199732020–00003.
 - Kantarjian H.M., O′Brien S., Cortes J., Giles F. J., Faderl S., Issa J. P., Garcia-Manero G., Rios M. B., Shan J., Andreeff M., Keating M., Talpaz M. Cancer. 2003, 98, 522–528. doi: 10.1002/cncr.11543.
 - Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., Houghton J. Lancet. 1994, 344, 1255–1260. doi: 10.1016/S0140–6736(94)90750–1.
 - Tournilhac O., Cazin B., Leprètre S., Diviné M., Maloum K., Delmer A., Grosbois B., Feugier P., Maloisel F., Villard F., Villemagne B., Bastit D., Belhadj K., Azar N., Michallet M., Manhès G., Travade P. Blood. 2004, 103, 363–365. doi: 10.1182/blood-2003–05–1449.
 - http://www.cancer.gov/cancertopics/druginfo/fda-nelarabine; Архивная копия от 11 сентября 2014 на Wayback Machine FDA Approval for Nelarabine.
 - Wangsomboonsiri W., Mahasirimongkol S., Chantarangsu S., Kiertiburanakul S., Charoenyingwattana A., Komindr S., Thongnak C., Mushiroda T., Nakamura Y., Chantratita W., Sungkanuparph S. Clin. Infect. Dis 2010, 50, 597–604. doi: 10.1086/650003.
 - Lai C.L., Leung N., Teo E. K., Tong M., Wong F., Hann H. W., Han S., Poynard T., Myers M., Chao G., Lloyd D., Brown N. A. Gastroenterology. 2005, 129, 528–536. doi: 10.1016/j.gastro.2005.05.053.
 - Wilhelmus K.R. Cochrane Database Syst Rev. 2015, 1, CD002898. doi: 10.1002/14651858.CD002898.pub5
 - Ko W.C., Rolain J. M., Lee N. Y., Chen P. L., Huang C. T., Lee P. I., Hsueh P. R. Int. J. Antimicrob. Agents. 2020, 55, 105933. doi: 10.1016/j.ijantimicag.2020.105933.
 - Hassan A.E.A., Abou-Elkhair R.A.I., Parker W. B., Allan P. W., Secrist III J. A. Eur. J. Med. Chem. 2016, 108, 616–622. doi: 10.1016/j.ejmech.2015.12.029.
 
Arquivos suplementares
				
			
						
						
					
						
						
									






